Borderline tuberculoid leprosy in childhood onset systemic lupus erythematosus patient

Carregando...
Imagem de Miniatura
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2015
Editora
SAGE PUBLICATIONS LTD
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
LUPUS, v.24, n.13, p.1448-1451, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Leprosy is a contagious and chronic systemic granulomatous disease caused by the bacillus Mycobacterium leprae. To our knowledge, no case of leprosy in a childhood-onset systemic lupus erythematosus (c-SLE) patient has been reported. For a period of 31 years, 312 c-SLE patients were followed at the Pediatric Rheumatology Unit of our University Hospital. One of them (0.3%) had tuberculoid leprosy skin lesions during the disease course and is here reported. A 10-year-old boy from Northwest of Brazil was diagnosed with c-SLE based on malar rash, photosensitivity, oral ulcers, lymphopenia, proteinuria, positive antinuclear antibodies, anti-double-stranded DNA, anti-Sm and anti-Ro/SSA autoantibodies. He was treated with prednisone, hydroxychloroquine and intravenous cyclophosphamide, followed by mycophenolate mofetil. At 12-years-old, he presented asymmetric skin lesions characterized by erythematous plaques with elevated external borders and hypochromic center with sensory loss. Peripheral nerve involvement was not evidenced. No history of familial cases of leprosy was reported, although the region where the patient resides is considered to be endemic for leprosy. Skin biopsy revealed a well-defined tuberculoid form. A marked thickening of nerves was observed, often destroyed by granulomas, without evidence of Mycobacterium leprae bacilli. At that time, the SLEDAI-2K score was 4 and he had been receiving prednisone 15mg/day, hydroxychloroquine 200mg/day and mycophenolate mofetil 3g/day. Paucibacillary treatment for leprosy with dapsone and rifampicine was also introduced. In conclusion, we have reported a rare case of leprosy in the course of c-SLE. Leprosy should always be considered in children and adolescents with lupus who present skin abnormalities, particularly with hypoesthesic or anesthesic cutaneous lesions.
Palavras-chave
Childhood-systemic lupus erythematosus, children, leprosy, immunosuppressive
Referências
  1. Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
  2. Lastoria JC, 2014, AN BRAS DERMATOL, V89, P205, DOI 10.1590/abd1806-4841.20142450
  3. Ribeiro FM, 2015, IMMUNOL RES, V61, P160, DOI 10.1007/s12026-014-8596-y
  4. Lastoria JC, 2014, AN BRAS DERMATOL, V89, P389, DOI 10.1590/abd1806-4841.20142460
  5. Moraes AJP, 2006, PEDIATR INT, V48, P48, DOI 10.1111/j.1442-200X.2006.02169.x
  6. Trindade MAB, 2011, TRANSPL INFECT DIS, V13, P63, DOI 10.1111/j.1399-3062.2010.00549.x
  7. Gladman DD, 2002, J RHEUMATOL, V29, P288
  8. Eichelmann K, 2013, Actas Dermosifiliogr, V104, P554, DOI 10.1016/j.adengl.2012.03.028
  9. Kustner EC, 2006, MED ORAL PATOL ORAL, V11, P474
  10. Lourenco DMR, 2014, LUPUS, V23, P1422, DOI 10.1177/0961203314544187
  11. Neder L, 2014, J PEDIAT-BRAZIL, V90, P457, DOI 10.1016/j.jped.2014.01.007
  12. Neder L, 2015, REV BRAS RE IN PRESS
  13. Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255